Acquisition of a 10% stake in Strongbridge, a commercial-stage biopharmaceutical company, by Novo Nordisk, a global health care company with 95 years of innovation and leadership in diabetes care. The purchase price was approximately $37m. “The upfront payment and equity investment from Novo Nordisk will significantly strengthen the Company’s overall financial position and marks a tremendous step forward in Strongbridge’s continued evolution as a company dedicated to rare diseases,” said Matthew Pauls, president and chief executive officer of Strongbridge Biopharma.